Compare Duolingo Inc (DUOL) vs Sanofi SA (SNY) Price & Performance

Duolingo (DUOL) trades at $149.92, down 1.19% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $0.66 versus $0.60, continuing a pattern of earnings outperformance. Revenue growth remains robust at 39% year-over-year for 2025, reaching $1.04 billion, while maintaining exceptional profitability with a 35.87% net income margin. Technical indicators show a bullish moving average configuration despite neutral oscillators.

Duolingo presents a compelling growth story with accelerating revenue expansion and industry-leading margins, though valuation multiples appear elevated with a P/E of 17.87 and P/S of 6.47. Key risks include CEO share sales totaling $4.3 million in September 2026 and competitive pressures in the edtech space. Analyst consensus leans cautious with 54% hold ratings, suggesting the stock may be fairly valued near current levels despite strong operational performance.

Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.

The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.